PREDICTIVE TECHNOLOGY GROUP NAMES BIOLOGIC INDUSTRY LEADER JEFF ACUFF AS CHIEF COMMERCIAL OFFICER OF PREDICTIVE BIOTECH

SALT LAKE CITY (August 23, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces the appointment of Jeff Acuff to the newly created position of Chief Commercial Officer of its wholly owned subsidiary Predictive Biotech.

Mr. Acuff will be responsible for the commercial strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P) business, and will implement programs and business development strategies aimed at driving sales and increasing physician awareness of HCT/P treatment options. He also will lead the commercial development of new product candidates, and the expansion and use of the human cell and tissue products into new vertical-market targets that include wound management and aesthetics. Additionally, he will oversee the long-term business development strategy for cellular therapies being developed by Predictive Therapeutics.

“Jeff brings a deep knowledge of the healthcare industry, a clear focus of physician and patient needs, and a proven track record of successful execution in ortho-biologic sales, which makes him ideally suited to lead the commercial efforts for Predictive Biotech, as well as the development of the Company’s sales expansion plans,” said Mr. Eric Olson, CEO of Predictive Biotech. “Under his leadership, I am confident we will continue to build upon the Company’s solid foundation in sales and strengthen our ability to bring quality products to our physician customers.”

“I am very excited and honored to lead such a talented and proven team as we continue to focus on building the Company’s portfolio and capabilities for the future,” said Mr. Acuff. “Predictive Biotech has made the safety, efficacy and quality of its human cell and tissue products the number one priority in serving physician customers and their patients. The Company has delivered over 95,000 allografts to date and is proud to serve as a reliable, quality manufacturer. I look forward to building upon these trusted customer relationships to best serve patient needs.”

Mr. Acuff has more than 25 years of commercial and leadership experience concentrated in the medical device and biologics industry, and has a proven track record for building high-performing teams and achieving exceptional results. He most recently served as the Commercial Excellence Leader for GE Healthcare. Prior to joining GE Healthcare, Mr. Acuff was Senior Vice President of Sales leading the commercial efforts of Bioventus, a private equity-owned ortho-biologics company, and was Vice President of Sales, Americas for Varian Medical Systems, where he helped develop and lead the commercial strategy and implementation for its radiation oncology business. Before that, he served for 13 years at Medtronic in various roles, including Vice President of Sales, Biologics and Vice President of Enabling Technologies Sales & Marketing. During his tenure at Medtronic, he led sales organizations in both mature and fast-growing market segments including interventional cardiology, interventional radiology, endovascular surgery, spine, and biologics.

Mr. Acuff holds a Bachelor of Business Administration in Management from the University of Memphis and completed an Executive Program at the Kellogg School of Management at Northwestern University.

About Predictive Biotech, Inc.

Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

For more information, visit www.predtechgroup.com 

Contacts:For more information, visit www.predtechgroup.com Relations:

PREDICTIVE TECHNOLOGY GROUP ACCELERATES RESEARCH SAMPLE COLLECTIONS TO SUPPORT DEVELOPMENT OF PERSONALIZED MOLECULAR DIAGNOSTICS AND CLINICAL THERAPIES

Subsidiary Predictive Laboratories hits milestone with 2,500 samples collected and processed since acquiring CLIA operations in March 2019; four new research sample collection initiatives set to begin this quarter   

SALT LAKE CITY (August 20, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories™ has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. Predictive is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility.

Research is conducted following strict protocols approved by external Institutional Review Boards.  Hundreds of individuals each month have voluntarily consented to share their medical histories and DNA samples for ongoing research. All research subjects are informed that their samples will be used in aggregate to develop new commercial diagnostic and therapeutic products. To ensure privacy, research samples and datasets are deidentified and securely stored.

Personalized medicine and the development of new therapeutics are expected to play a critical role in human health. Access to high-quality biospecimens from Predictive’s biobank will be crucial for furthering the Company’s biomedical and translational research, and ultimately its development of personalized molecular diagnostics and clinical therapies. Current sample collection efforts are designed to strategically augment Predictive’s existing library of over 300,000 DNA samples that the Company believes will produce valuable insights into future research and development projects.

The development of effective diagnostic and treatment products requires identification of genetic markers that are useful for early detection, prevention, and personalized treatment of specific medical conditions. Genetic discoveries lead to insights into the cause and progression of disease and often suggest novel means of treating serious chronic conditions.  Modern genetic research requires large numbers of well-characterized samples; one set for discovery, another independent set for replication, a third for validation, and a fourth to prove the clinical utility. 

“The ability to discover specific genetic markers related to the diagnosis, prognosis, and therapeutic response for disease targets can help Predictive find solutions that could transform medical care,” said Bradley Robinson, CEO of Predictive Technology Group. “A crucial requirement for personalized medicine is the availability of an extensive collection of both human diseased and healthy samples with well-documented medical records.

“Through investment in our biobank initiatives and collaboration with others who have relevant research collections, we reached this new collection milestone of 2,500 samples very rapidly and we continue to build on our database,” he added. “At Predictive Laboratories, we have state-of-the-art capabilities for automated DNA extraction, sample handling, and high-throughput genotyping and sequencing that support our planned development of breakthrough diagnostics and therapeutics.”

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP ANNOUNCES LAUNCH OF PGxPLUS+™ PHARMACOGENOMIC TEST AND REACHES CLINICAL STUDY ENROLLMENT MILESTONE

Enrollment reaches 350 patients for IRB-approved study focused on chronic pain

SALT LAKE CITY (August 9, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain.  PGxPLUS+ evaluates genetic factors that play a major role in an individual’s response to medications.  In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.

Predictive Technology Group is tackling chronic pain and the opioid crisis on multiple fronts. Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain.  In 2016, the Institute of Medicine estimated that up to one-third of the U.S. population lives with ongoing pain.  Chronic pain is often triggered by one of these common conditions, and over time can develop into a chronic pain syndrome, which is a disease itself.

The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests available on the market.  Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications.  More than 90% of the population has one or more gene variants that affect the efficacy or safety of prescription drugs.  Variation in drug metabolism is largely determined by an individual’s genetic profile, blood levels of a drug may vary up to 1,000-fold in similar patients taking identical doses of the same drug.  Pharmacogenomics is the study of the role of our genome in drug responses.

Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+ pharmacogenetic test has been very helpful in my day-to-day practice.  The results give insights into why some patients are not responding to medications as expected.  With the help of these test results, I have been able to start or switch medications for patients more successfully.  The PGxPLUS+ test helps me avoid prescribing medications that a patient won’t metabolize well, leading to better and more personalized patient care.” 

One-third of patients taking long-term opioid therapy for non-cancer chronic pain either find their medication to be ineffective or they do not tolerate the side effects of the treatment. In the clinical study, Predictive is testing patients who are taking high doses of opioids [≥50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction.  Predictive plans to develop more comprehensive treatment guidelines for pain based on predictive genetic markers. 

“The ability to effectively treat individuals in pain represents a significant market opportunity and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual in a safer and more effective manner,” said Bradley Robinson, CEO of Predictive Technology Group.  “Our Company is both identifying the most effective ways to treat pain at a personalized level and working to understand the underlying cause of diseases like osteoarthritis, lumbar disc disease and endometriosis to treat or prevent the root cause of the pain.  We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases.”

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com

Predictive Technology Group Names Industry Veteran Dr. E. Robert Wassman Co-Laboratory Director of Predictive Laboratories

Dr. Wassman brings 35 years of genetics diagnostic and personalized medicine experience, and significant expertise to lead the cytogenetics section of Predictive Laboratories

SALT LAKE CITY (August 6, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the appointment of E. Robert Wassman, M.D. as Co-Laboratory Director of Predictive Laboratories. 

Dr. Wassman has been pioneering the introduction of genetic testing and personalized medicine for over 35 years. Throughout his career, he has focused on the translation and delivery of cutting-edge diagnostic technology to clinical services in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and next-generation DNA sequencing. He brings Predictive Laboratories critical expertise in reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism. Dr. Wassman is a graduate of Yale University and Albany Medical College and he is Board Certified in Pediatrics and Medical Genetics.

Dr. Wassman previously served as Chief Medical Officer for multiple companies in the genetic testing space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics and Alfigen. He co-founded several successful ventures and served as a consultant to a wide variety of entities ranging from large to small clinical laboratories, IVD and biotech companies, investment groups, regulatory agencies, payers and legal firms.

In addition to clinical and technical expertise, Dr. Wassman has laboratory and general operational, business development, medical affairs/marketing and sales experience in the U.S., Europe, Japan and China. He has formal training and both public and private sector experience in reimbursement and managed care. Dr. Wassman currently serves on the Board of Directors and Scientific Advisory Board of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5 epileptic encephalopathy.

“We are delighted that Dr. Wassman is joining our outstanding team at Predictive Laboratories,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Wassman’s strategic insights, deep scientific and medical knowledge, and quick study abilities have enabled him to play a pivotal role in numerous firsts in reproductive genetics including expanded maternal serum screening, the first nationwide Pre-Implantation Genetic (PGD) test, and the first commercially successful clinical NGS-based testing for carrier screening in IVF clinics. We welcome him to Predictive Laboratories and look forward to his contributions as we expand our genetic-based diagnostics.”

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com 

Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility

American Society of Reproductive Medicine selects findings through scientific peer-review process for presentations at the 75th ASRM Scientific Congress & Expo in October

SALT LAKE CITY (August 2, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), announces the presentation of new genetic findings in endometriosis at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo being held October 12-16, 2019 in Philadelphia. The new findings will be presented by Predictive Laboratories’ scientific team. Predictive Technology Group is a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention.

Three scientific presentations (two oral and one poster) highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.

Endometriosis affects more than 10 million women in the United States. It occurs when tissue similar to the lining of the uterus (womb) appears in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others have problems with their menstrual periods, and some have no symptoms at all. Treatment may involve hormonal suppression or surgical destruction of the abnormal tissue.

“We are very pleased with the acceptance of these presentations by ASRM and to be presenting this important data to the thousands of researchers and physicians attending the ASRM meetings,” said Bradley Robinson, CEO of Predictive Technology Group. “Most importantly we look forward to these discoveries being applied in clinical settings to reduce the suffering of millions of women around the world and aiding to eliminate or reduce the related complications of this debilitating disease. 

“We look forward to announcing these data following the presentations at ASRM meeting,” he added.  “I’m delighted with the commitment of our scientific team and its dedication in continuing to expand the understanding of endometriosis.”  

The Company’s population genetics research underlies its novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility currently launched to select collaborators by Predictive Laboratories.  

ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com

Predictive Laboratories Announces Research Collaboration with the Preeclampsia Foundation

Collaboration to expand the study of genetic factors contributing to preeclampsia and support Predictive Laboratories’ development of personalized products to detect preeclampsia risk before and during pregnancy

SALT LAKE CITY, UT- July 31, 2019 –  Predictive Technology Group, Inc. (OTCPINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces that its wholly owned subsidiary Predictive Laboratories has entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with preeclampsia. The study will advance the Preeclampsia Foundation’s database of collected preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.

Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, sometimes causing severe adverse maternal and fetal outcomes, including organ failure, massive blood loss, permanent disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually are attributable to preeclampsia. Healthcare providers, even in medically advanced countries, are hampered by imprecise diagnostic tools.

The Preeclampsia Registry, a key program of the Preeclampsia Foundation’s research mission, is a patient registry that collects paired medical information and biological samples. Using established Institutional Review Board-approved protocols, Predictive Laboratories and the Preeclampsia Foundation will request samples from more than 2,500 existing and new registry participants for sequencing analysis. Predictive Laboratories has been granted a period of exclusive access to research data resulting from these new samples enrolled in the Preeclampsia Registry, after which samples and sequencing data will be available to other investigators for future research.

“The Preeclampsia Foundation created an empowered community of patients and experts with a diverse array of resources, support and advocacy to help women have the best possible outcomes from their pregnancies,” said Bradley Robinson, CEO of Predictive Technology Group. “We look forward to enhancing our partnership, helping to grow the Preeclampsia Registry resource and developing innovative and effective products aimed at the early detection and treatment of this devastating medical condition.”

This collaboration complements and extends ongoing preeclampsia research initiatives at Predictive Laboratories. Over 20,000 DNA samples from Predictive’s biorepository relating to preeclampsia and associated obstetric syndromes are being analyzed. Predictive Laboratories’ pending patent applications relating to predictive genetic markers of preeclampsia were acquired through its acquisition of Taueret Laboratories, which was completed in March 2019. Prior to acquisition, the Taueret Laboratories team had a long history of collaboration with the Preeclampsia Foundation and invested significant resources towards genotyping and sequencing thousands of samples during discovery work. The combination of knowledge and resources under the Predictive Laboratories subsidiary represents a strong pipeline for developing novel DNA based products.

“We envision a world where preeclampsia no longer threatens the lives of mothers and their babies,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “In addition to a diagnostic test Predictive Laboratories may develop, this infusion of genomic data to our already robust registry accelerates our research agenda and brings us closer to making our vision a reality.”

About the Preeclampsia Foundation
Established in 2000, the Preeclampsia Foundation is the only 501(c)(3) not-for-profit patient advocacy organization representing the 5-8% of pregnant women and their babies who are affected by life-threatening hypertensive disorders of pregnancy, such as preeclampsia, eclampsia, and HELLP syndrome. The Foundation is advised by a medical board comprised of top medical and scientific experts and works collaboratively with many other stakeholders to achieve its mission of improving the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. Additional information is available at Preeclampsia.org and Preeclampsiaregistry.org.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact: For more information, visit www.predtechgroup.com

Predictive Technology Group announces its 11th Consecutive Quarter of Revenue Growth

Affirms business strategy and milestones

SALT LAKE CITY (July 15, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.

“We are proud of our revenue growth, fundamentals and business momentum. We continue to make excellent progress with our strategy to increase sales from our human cell and tissue products, while preparing for the full commercial launch in the coming quarters of our genetic-based endometriosis and fertility diagnostic/prognostic tests,” said Bradley Robinson, CEO of Predictive Technology Group.

“Over the past several months we made significant strides in building a strong infrastructure,” Robinson added. “We strengthened our executive leadership and our board of directors, announced a key global collaboration with Thermo Fisher Scientific to better understand the genetic factors underlying infertility, and presented new genetic data at key industry conferences. We also completed the integration of two DNA laboratories into Predictive Laboratories at a much faster pace than anticipated, and appointed experienced industry veterans to lead this state-of-the-art facility. Additionally, we filed a Form 10 with the United States Securities and Exchange Commission (US SEC) that is effective, making Predictive Technology Group a full reporting 1934 Exchange Act compliant company. And, we submitted an application, which is currently under review, to list Predictive Technology Group’s common stock for trading on The NASDAQ Stock Market.”

The Company expects to report its fourth quarter and fiscal 2019 full year financial results in September 2019. 

Predictive is aware that a short-seller recently issued a critical opinion piece regarding the Company in an attempt to manipulate the Company’s stock price.  “This opinion piece was produced by anonymous author(s) who admit in the opinion piece that they ‘have taken a really large short position in shares’ of our Company and ‘stand to benefit financially if the stock price declines,’” said John Sorrentino, Chairman of Predictive Technology Group.  “As stated in the short-seller opinion’s disclaimers, the anonymous authors refuse to stand behind their allegations – they make ‘no representation, express or implied, as to the accuracy, timeliness, or completeness of [the opinion’s] information. . .’   Given that the short-seller opinion is intended to drive down the price of the Company’s stock and the opinion’s authors have refused to guarantee the accuracy of the ‘information’ the opinion espouses, the Company will not dignify the opinion piece with a point-by-point response. The Company remains focused on developing products that have the potential to improve the quality of life for people throughout the world.”

The Company notes, however, that some of the topics raised in the piece – including the Company’s recent acquisitions – are fully disclosed, in detail, in the Company’s filings with the US SEC.  The Company encourages stakeholders to review the detail of these transactions in its US SEC Edgar filings.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:

For more information, visit www.predtechgroup.com

PREDICTIVE TECHNOLOGY GROUP ANNOUNCES THE PRESENTATION OF NEW GENETIC FINDINGS IN ENDOMETRIOSIS AT THE 35TH ANNUAL MEETING OF THE EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY

SALT LAKE CITY (June 20, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Kenneth Ward, M.D. will present new genetic findings in endometriosis at the 2019 European Society of Human Reproduction and Embryology (ESHRE) meeting on Monday, June 24 in Vienna, Austria.

Dr. Ward is CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau Biosciences and is Juneau Biosciences’ largest shareholder.

“Predictive is committed to understanding the biology, diagnosis and treatment of endometriosis,” said Bradley Robinson, President and CEO of Predictive Technology Group. “We are thrilled to contribute to the scientific understanding of a disease that has been difficult to treat and believe our investigative efforts will lead to improved patient outcomes in the future.”

Details on the presentation at ESRHE 2019 are as follows:

Abstract Title:  Excess Germline Mutations in Four Genes in Unrelated Women with Surgical Endometriosis

Presenting Author:  Dr. Kenneth Ward

Presentation Details:  Monday, June 24 at 15:30 CEST

           Session 23

Room: Strauss 1+2

A press release summarizing the presented data will be issued following the presentation at ESHRE.

About ESHRE

The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world’s major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.

Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:

For more information, visit www.predtechgroup.com

Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration

Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment

CARLSBAD, Calif., June 19, 2019 /PRNewswire/ — Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher’s various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.

Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as “unexplained.” The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.

Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.

“Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions,” said Bradley Robinson, CEO of Predictive Technology Group. “Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.”

Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.

“We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women,” said Yan Zhang, general manager, reproductive health at Thermo Fisher. “With the combination of our partner’s expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.”

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.

Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com

Predictive Technology Group Names Industry Veteran Dr. Douglas Rabin Vice President of Medical Affairs, Women’s Health of Predictive Laboratories

Appointment expands Predictive Laboratories’ management team to support goal of bringing innovative molecular diagnostics to market

 SALT LAKE CITY, June 04, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women’s health clinical franchise. Dr. Rabin has more than 25 years of experience in women’s healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.

 Dr. Rabin previously served as Medical Director for Women’s Health at Quest Diagnostics, where he successfully completed a seminal paper in cervical cancer screening, initiated a trial in BRCA population testing and helped launch Quest’s non-invasive prenatal and Jewish genetic diagnostics. He also was instrumental in the expansion of the women’s health franchise at Quest through the acquisition of Reprosource, Inc. He previously was a National Health Service Corps (NHSC) physician, and a National Scholarship Awardee at the National Institutes of Health (NIH) and its gynecological consultant, as well as a consultant to multiple Big Four accounting firms. His clinical credentials include management of a successful in vitro fertilization (IVF) practice for more than 10 years and as a full-time obstetrician and gynecologist. In addition, Dr. Rabin served as the medical director for a pharmaceutical company addressing women’s health issues.

 Dr. Rabin earned a bachelor’s degree in economics from Harvard College and a medical degree from the Temple University School of Medicine. He completed his Ob/Gyn training at the Hospital of the University of Pennsylvania and spent eight years at the NIH after completing a fellowship in endocrinology and infertility at Mt Sinai School of Medicine.

 Dr. Rabin said, “I am extremely excited to join Predictive Technology Group. I view our diagnostics to identify patients with endometriosis as novel predictive approaches in managing fertility, pelvic pain and improving women’s lives.”

 “We welcome Dr. Rabin to the Predictive team to support our goal of commercializing our innovative, genetic-based diagnostics that are initially focus on human infertility and women’s health,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Rabin is highly accomplished in launching pharmaceutical and diagnostic products at Fortune 500 companies. His experience and commitment to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in supporting our mission of employing advanced molecular diagnostics to prevent or eliminate disease for generations to come.”

 About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). Its novel test for women experiencing infertility, ARTGuide™, was launched in late 2018 to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as IVF, are used to assist couples having difficulty conceiving a pregnancy.

 About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.